Company

Excerpts from Customer and Partner Posters:

"The RapidFire System directly couples SPE to MS analysis, and that facilitates automated sample purification and MS analysis."

"RF-MS provides data quality comparable to LC-MS systems, but with a ~30-fold increase in speed. This increased throughput enables quantitative analyses of CYP450 inhibition in a 7-point dose-response format."

"RapidFire in conjunction with Agilent 6220 ESI-TOF MS provides a platform for:
• Label-free screening of whole protein kinase assays
• Quantitative measurement of multiple modifications to full length native proteins
• Sustained throughputs of 10-12 seconds/sample"

Company Overview

BIOCIUS Life Sciences, Inc. is a privately held company committed to collaborating with researchers to advance drug discovery research. Using RapidFire® technology, BIOCIUS helps to eliminate bottlenecks for lead discovery and in vitro ADME . The RapidFire system enables researchers to gain a more complete understanding of the biochemical properties of potential lead compounds, including potential liabilities in drug-drug interactions using high-throughput mass spectrometry (MS).

RapidFire technology uses innovative microfluidics for an SPE-based solution, enabling detection of native compounds. RapidFire MS is 10 to 100 times faster than conventional MS screening methods. Requiring no labels or surrogates, RapidFire enables the screening of intractable or challenging targets which are not amenable to fluorescence or luminescence.

Available as hardware for our clients’ laboratories or as a contract research service at BIOCIUS, RapidFire technology provides life science researchers with shortened time to results, accurate data and greater potential for success.

BIOCIUS. Faster Answers.

RapidFire® technology is described in patent numbers 6,932,939, 6,812,030 7,100,460, 7,588,725,